Articles

Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma

Montefiore-Einstein Cancer Center, Montefiore Medical Center, Bronx, NY, USA;
University of Arkansas for Medical Sciences, Little Rock, AR, USA;
University of California, San Francisco, San Francisco, CA, USA;
University of Miami, Sylvester Comprehensive Cancer Center, Miami, USA;
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA;
Moores University of California, San Diego Cancer Center, La Jolla, CA, USA;
Virginia Mason Cancer Institute, Seattle, WA, USA;
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA;
University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA, USA;
Washington University, St. Louis, MO, USA;
Weill Medical College of Cornell University, New York, NY, USA;
Weill Cornell Medical College, New York, NY, USA;
University of California, Los Angeles Medical Center, Los Angeles, CA, USA
Vol. 106 No. 3 (2021): March, 2021 https://doi.org/10.3324/haematol.2019.243386